{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:04:22Z","timestamp":1782929062631,"version":"3.54.5"},"reference-count":256,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022\\u202FJ01671"],"award-info":[{"award-number":["2022\\u202FJ01671"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204324"],"award-info":[{"award-number":["82204324"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102118"],"award-info":[{"award-number":["82102118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072263"],"award-info":[{"award-number":["82072263"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Shenzhen Science and Technology Innovation Committee","doi-asserted-by":"publisher","award":["RCBS20210706092256079"],"award-info":[{"award-number":["RCBS20210706092256079"]}],"id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","award":["SZSM202301035"],"award-info":[{"award-number":["SZSM202301035"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ijbiomac.2025.143134","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T08:00:59Z","timestamp":1744617659000},"page":"143134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P4","title":["mRNA-based vaccines and therapies - a revolutionary approach for conquering fast-spreading infections and other clinical applications: a review"],"prefix":"10.1016","volume":"309","author":[{"given":"Mingyue","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiling","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.143134_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020622","article-title":"mRNA-based therapeutics in cancer treatment","volume":"15","author":"Sun","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0010","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct Tar"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0015","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1093\/nar\/12.18.7057","article-title":"Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs","volume":"12","author":"Krieg","year":"1984","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0020","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid nanoparticle technology for clinical translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100424","article-title":"Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs","volume":"41","author":"Suzuki","year":"2021","journal-title":"Drug Metab Pharmacok"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0030","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/j.apsb.2023.01.018","article-title":"Microfluidics for nano-drug delivery systems: from fundamentals to industrialization","volume":"13","author":"Zhang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0035","doi-asserted-by":"crossref","first-page":"14839","DOI":"10.1021\/acsami.9b22781","article-title":"Microfluidic-based holonomic constraints of siRNA in the kernel of lipid\/polymer hybrid nanoassemblies for improving stable and safe in vivo delivery","volume":"12","author":"Wei","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0076-6879(03)67004-7","article-title":"Liposomes prepared by high-pressure homogenizers","volume":"367","author":"Rodr\u00edguez","year":"2003","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0045","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0055","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s40521-022-00311-8","article-title":"Adverse reactions to anti-infective vaccines: an emerging problem in the COVID-19 era","volume":"9","author":"Escudero","year":"2022","journal-title":"Curr. Treat. Options Allergy"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0065","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/CIRCULATIONAHA.122.060961","article-title":"Myocarditis after BNT162b2 COVID-19 third booster vaccine in Israel","volume":"146","author":"Mevorach","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0070","doi-asserted-by":"crossref","unstructured":"Oueijan R.I., Hill O.R., Ahiawodzi P.D. at al., Rare heterogeneous adverse events associated with mRNA-based COVID-19 vaccines: A Systematic Review, Medicines 9 (2022) 43. doi:https:\/\/doi.org\/10.3390\/medicines9080043.","DOI":"10.3390\/medicines9080043"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0075","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/15563650.2022.2147272","article-title":"An observational study of adverse drug reactions to COVID-19 vaccines reported to the New Mexico poison center hotline","volume":"61","author":"Tadfor","year":"2023","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0080","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaip.2022.08.048","article-title":"Clinical phenotypes of immediate first-dose reactions to mRNA COVID-19: a multicenter latent class analysis","volume":"11","author":"Stone","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0085","first-page":"2559","article-title":"COVID-19 vaccine-related pathologies: cardiac and neurological side effects and Long-term COVID-1","volume":"27","author":"Beril","year":"2023","journal-title":"J RES PHARM"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102941","article-title":"Autoimmunity roots of the thrombotic events after COVID-19 vaccination","volume":"20","author":"Elrashdy","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0095","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/vaccines11050915","article-title":"Polyethylene glycol and polysorbate 80 skin tests in the context of an allergic risk assessment for hypersensitivity reactions to anti-SARS-CoV-2 mRNA vaccines","volume":"11","author":"Nappi","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0100","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.alit.2022.05.007","article-title":"Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines","volume":"71","author":"Mouri","year":"2022","journal-title":"Allergol. Int."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0105","unstructured":"Moderna. Moderna announces longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures, https:\/\/www.businesswire.com\/news\/home\/20201116005606\/en\/Moderna-Announces-Longer-Shelf-Life-for-its-COVID-19-Vaccine-Candidate-at-Refrigerated-Temperatures2020 (accessed 12 October 2023)."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0110","first-page":"205","article-title":"at al","volume":"25","author":"Gerhardt","year":"2022","journal-title":"A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery, Mol Ther-Meth Clin D"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0115","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","article-title":"Lyophilization provides Long-term stability for a lipid nanoparticle-formulated, nucleoside-modified Mrna vaccine","volume":"30","author":"Muramatsu","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0120","series-title":"A 5\u2019 UTR Language Model for Decoding Untranslated Regions of mRNA and Function Predictions, bioRxiv Preprint","author":"Chu","year":"2023"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0125","first-page":"179","article-title":"and EL-Kebir M","volume":"31","author":"Gu","year":"2024","journal-title":"DERNA enables pareto optimal RNA design, J Comput Biol"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0130","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4161\/15476286.2014.992278","article-title":"Pseudouridine: still mysterious, but never a fake (uridine)!","volume":"11","author":"Spenkuch","year":"2014","journal-title":"RNA Biol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0135","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0140","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41577-021-00608-w","article-title":"Modified uridines are the key to a successful message","volume":"21","author":"Karik\u00f3","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0150","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jconrel.2021.11.022","article-title":"Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery","volume":"341","author":"Melamed","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0155","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.3390\/ijms21145130","article-title":"Viruses as RNA Vaccines","volume":"21","author":"Lundstrom","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0160","article-title":"Development and delivery systems of mRNA vaccines","volume":"9","author":"Liang","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0165","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1261\/rna.990208","article-title":"Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS","volume":"14","author":"Kowalska","year":"2008","journal-title":"RNA"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0170","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1080\/15384101.2018.1486164","article-title":"Modified ARCA analogs providing enhanced translational properties of capped mRNAs","volume":"17","author":"Kocmik","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0175","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3390\/polym12081633","article-title":"Enzymatic protein biopolymers as a tool to synthetize eukaryotic messenger ribonucleic acid (mRNA) with uses in vaccination, immunotherapy and nanotechnology","volume":"12","author":"Urbina","year":"2020","journal-title":"Polymers"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0180","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/bs.ircmb.2022.04.011","article-title":"Advances in mRNA vaccines","volume":"372","author":"Li","year":"2022","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0185","doi-asserted-by":"crossref","unstructured":"Xiang K. Bartel D.P., The molecular basis of coupling between poly(a)-tail length and translational efficiency, eLife 10 (2021) 1\u201339. doi:https:\/\/doi.org\/10.7554\/eLife.66493.","DOI":"10.7554\/eLife.66493"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0190","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.semcdb.2014.05.018","article-title":"Determinants and implications of mRNA poly(A) tail size--does this protein make my tail look big?","volume":"34","author":"Jalkanen","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0195","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.bbrc.2005.12.105","article-title":"mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with poly(a) chains in cis and in trans for a high protein expression level","volume":"340","author":"Mockey","year":"2006","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0200","doi-asserted-by":"crossref","unstructured":"Hillery A.M., The science of mRNA: structure, design innovations and synthesis via IVT, mRNA Ther (2025) 67\u201394. doi:https:\/\/doi.org\/10.1016\/B978-0-443-28934-7.00003-0.","DOI":"10.1016\/B978-0-443-28934-7.00003-0"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2024.168804","article-title":"Rational design of untranslated regions to enhance gene expression","volume":"436","author":"Liu","year":"2024","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0210","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/cells13151242","article-title":"Synthetic mRNAs containing minimalistic untranslated regions are highly functional in vitro and in vivo","volume":"13","author":"Mamaghani","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0215","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.3390\/ijms21186582","article-title":"mRNA vaccine era\u2014mechanisms, drug platform and clinical prospection","volume":"21","author":"Xu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0225","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/0008-5472.CAN-08-3920","article-title":"In situ expression of tumor antigens by messenger RNA\u2013electroporated dendritic cells in lymph nodes of melanoma patients","volume":"69","author":"Schuurhuis","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0230","first-page":"1","article-title":"mRNA-based HIV-1 vaccines","volume":"37","author":"Herschhorn","year":"2024","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0235","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1638212","article-title":"Trial watch: dendritic cell vaccination for cancer immunotherapy","volume":"8","author":"Sprooten","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0240","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","article-title":"Dendritic cell biology and its role in tumor immunotherapy","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0245","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14653240902960411","article-title":"Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial","volume":"11","author":"Van Driessche","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0250","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.16197","article-title":"HIV and messenger RNA vaccine","author":"Khalid","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0255","series-title":"Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-1-4939-6481-9_12","article-title":"Enhanced delivery of DNA or RNA vaccines by electroporation","author":"Broderick","year":"2017"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0260","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2017.07.027","article-title":"Protein-RNA complexation driven by the charge regulation mechanism","volume":"498","author":"Barroso da Silva","year":"2018","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0265","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/pharmaceutics13060877","article-title":"Protamine-based strategies for RNA transfection","volume":"13","author":"Jarzebska","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0270","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/vaccines7040132","article-title":"Advances in RNA vaccines for preventive indications: a case study of a vaccine against rabies","volume":"7","author":"Armbruster","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0275","first-page":"89","article-title":"RNActive\u00ae technology: generation and testing of stable and immunogenic mRNA vaccines","volume":"2017","author":"Rauch","year":"2017","journal-title":"Methods in molecular biology, Humana Press, New York"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0280","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0285","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/10717544.2020.1790692","article-title":"Functional differences between protamine preparations for the transfection of mRNA","volume":"27","author":"Jarzebska","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0290","article-title":"mRNA vaccines in the prevention and treatment of diseases","volume":"3","author":"Gu","year":"2022","journal-title":"Media Commun."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0295","doi-asserted-by":"crossref","first-page":"eaav8521","DOI":"10.1126\/scitranslmed.aav8521","article-title":"Advances in therapeutic applications of extracellular vesicles","volume":"11","author":"Wiklander","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0300","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3390\/cells9040851","article-title":"Targeting and crossing the blood-brain barrier with extracellular vesicles","volume":"9","author":"Saint-Pol","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0305","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s12276-019-0223-5","article-title":"Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking","volume":"51","author":"Murphy","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0310","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13287-020-02088-6","article-title":"Human umbilical cord mesenchymal stem cell-derived extracellular vesicles ameliorate airway inflammation in a rat model of chronic obstructive pulmonary disease (COPD)","volume":"12","author":"Ridzuan","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0315","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.3390\/ijms24044026","article-title":"Natural killer cell-derived extracellular vesicles as a promising immunotherapeutic strategy for cancer: a systematic review","volume":"24","author":"Chan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0320","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-17-0827","article-title":"Anti-HER2 scFv-directed extracellular vesicle-mediated mRNA-based gene delivery inhibits growth of HER2-positive human breast tumor xenografts by prodrug activation","volume":"17","author":"Wang","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.1054324","article-title":"Exploiting the potential of extracellular vesicles as delivery vehicles for the treatment of melanoma","volume":"10","author":"Hou","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0330","doi-asserted-by":"crossref","unstructured":"Tsai S.J., Atai N.A., Cacciottolo M. et al., Exosome-mediated mRNA delivery in vivo is safe and can used to induce SARS-CoV-2 immunity, J. Biol. Chem. 297 (2021) 101266. https:\/\/doi.https:\/\/doi.org\/10.1016\/j.jbc.2021.101266.","DOI":"10.1016\/j.jbc.2021.101266"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0335","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.chest.2023.06.024","article-title":"Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for the treatment of respiratory failure from COVID-19","volume":"164","author":"Lightner","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0340","article-title":"Nanoscale platforms for messenger RNA delivery","volume":"11","author":"Li","year":"2018","journal-title":"WIREs Nanomed Nanobi"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0345","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0350","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1472-6750-13-75","article-title":"Exogenous mRNA delivery and bioavailability in gene transfer mediated by piggyBac transposition","volume":"13","author":"Bire","year":"2013","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0355","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.reth.2022.12.008","article-title":"Introduction of tenomodulin by gene transfection vectors for rat bone tissue regeneration","volume":"22","author":"Wang","year":"2023","journal-title":"Regen Ther"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0360","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2015.12.032","article-title":"Materials for non-viral intracellular delivery of messenger RNA therapeutics","volume":"240","author":"Kauffman","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0365","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1039\/D1CS00686J","article-title":"Andfester K., polymer nano-systems for the encapsulation and delivery of active biomacromolecular therapetic agents","volume":"51","author":"Machtakova","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0370","first-page":"29","article-title":"Biomaterial-assisted biotherapy: a brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy","volume":"17","author":"Han","year":"2022","journal-title":"Bioact Mater"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0375","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1021\/acs.nanolett.5b02428","article-title":"Poly(glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo","volume":"16","author":"Dong","year":"2016","journal-title":"Nano Lett."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0380","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jconrel.2016.12.005","article-title":"Self-aggregating 1.8 kDa polyethylenimines with dissolution switch at endosomal acidic pH are delivery carriers for plasmid DNA, mRNA, siRNA and exon-skipping oligonucleotides","volume":"246","author":"Chiper","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0385","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.msec.2018.07.027","article-title":"Polyester-based nanoparticles for nucleic acid delivery","volume":"92","author":"Zhao","year":"2018","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0390","doi-asserted-by":"crossref","first-page":"2202688","DOI":"10.1002\/adhm.202202688","article-title":"Polymer-based mRNA delivery strategies for advanced therapies","author":"Yang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0395","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/molecules23040938","article-title":"Dendrimers for drug delivery","volume":"23","author":"Singh","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0400","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jconrel.2023.03.011","article-title":"Precise and systematic end group chemistry modifications on PAMAM and poly(l-lysine) dendrimers to improve cytosolic delivery of mRNA","volume":"356","author":"Joubert","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0405","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3390\/pharmaceutics14061205","article-title":"Polymeric micelles with pH-responsive cross-linked core enhance in vivo mRNA delivery","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0410","doi-asserted-by":"crossref","unstructured":"Hickey J.C., Hurst P.J., Patterson J.P. et al., Facile synthesis of multifunctional bioreducible polymers for mRNA delivery, Chem\u2013Eur J 29 (2023) 1\u20137. doi:https:\/\/doi.org\/10.1002\/chem.202203393.","DOI":"10.1002\/chem.202203393"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0415","article-title":"High-density brush-shaped polymer lipids reduce anti-PEG antibody binding for repeated administration of mRNA therapeutics","author":"Xiao","year":"2025","journal-title":"Nat. Mater."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0420","article-title":"Lipid carriers for mRNA delivery","author":"Zhang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119291","article-title":"RNA delivery biomaterials for the treatment of genetic and rare diseases","volume":"217","author":"Zhao","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0430","article-title":"Recent advances in site-specific lipid nanoparticles for mRNA delivery","author":"Xu","year":"2023","journal-title":"ACS Nanosci Au"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0435","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved efficacy in a fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0440","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol Thera"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0445","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.2147\/IJN.S363990","article-title":"Optimization of lipid nanoformulations for effective mRNA delivery","volume":"17","author":"Chen","year":"2022","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0450","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/s12951-024-02919-1","article-title":"High-throughput synthesis and optimization of ionizable lipids through A3 coupling for efcient mRNA delivery","volume":"22","author":"Li","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0455","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/s41467-024-45537-z","article-title":"In situ combinatorial synthesis of degradable branched lipidoids for systemic delivery of mRNA therapeutics and gene editors","volume":"15","author":"Han","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0460","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/jbm.a.37705","article-title":"Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length","volume":"112","author":"Mrksich","year":"2024","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0465","doi-asserted-by":"crossref","first-page":"13552","DOI":"10.1021\/acsami.4c21289","article-title":"Ionizable lipids with branched linkers enhance the delivery of mRNA vaccines","volume":"17","author":"Liu","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0470","doi-asserted-by":"crossref","first-page":"2415643","DOI":"10.1002\/adma.202415643","article-title":"Modular design of lipopeptide-based organ-specific targeting (POST) lipid nanoparticles for highly efficient RNA delivery","author":"Tang","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0475","article-title":"Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery","volume":"122","author":"Xu","year":"2025","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0480","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114098","article-title":"Attenuating ribosome load improves protein output from mRNA by limiting translation-dependent mRNA decay","volume":"43","author":"Bicknell","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0490","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","article-title":"Lipid nanoparticle technology for therapeutic gene regulation in the liver","volume":"159","author":"Witzigmann","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0495","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020401118","article-title":"Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3","volume":"118","author":"Qiu","year":"2021","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0500","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1039\/D0BM01609H","article-title":"Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0505","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1021\/acs.molpharmaceut.2c00442","article-title":"Lipid nanoparticle (LNP) chemistry can endow unique in vivo RNA delivery fates within the liver that alter therapeutic outcomes in a cancer model","volume":"19","author":"Johnson","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0510","doi-asserted-by":"crossref","first-page":"eabf4398","DOI":"10.1126\/sciadv.abf4398","article-title":"Engineered ionizable lipid nanoparticles fortargeted delivery of RNA therapeutics into different types of cells in the liver","volume":"7","author":"Kim","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0515","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/978-1-0716-2128-8_24","article-title":"Preparation and characterization of a liver targeted, poly(amidoamine) based, gene delivery system","volume":"2455","author":"Ebeid","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0520","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10486","article-title":"Galactosylated hydroxyl-polyamidoamine dendrimer targets hepatocytes and improves therapeutic outcomes in a severe model of acetaminophen poisoning-induced liver failure","volume":"8","author":"Porterfield","year":"2023","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0525","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1021\/acs.nanolett.2c01784","article-title":"Helper-polymer based five-element nanoparticles (FNPs) for lung-specific mRNA delivery with long-term stability after lyophilization","volume":"22","author":"Cao","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0530","article-title":"Inhaled nanoformulated mRNA polyplexes for protein production in lung epithelium","volume":"31","author":"Patel","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0535","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41563-022-01404-0","article-title":"Species-agnostic polymeric formulations for inhalable messenger RNA delivery to the lung","volume":"22","author":"Rotolo","year":"2022","journal-title":"Nat. Mater."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0540","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116271119","article-title":"Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis","volume":"119","author":"Qiu","year":"2022","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0545","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.matt.2022.06.012","article-title":"Inhalable dry powder mRNA vaccines based on extracellular vesicles","volume":"5","author":"Popowski","year":"2022","journal-title":"Matter"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0550","article-title":"Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy","author":"Witten","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0555","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40291-020-00467-6","article-title":"Improving molecular therapy in the kidney","volume":"24","author":"Rubin","year":"2020","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0560","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/nano6010008","article-title":"Targeted sterically stabilized phospholipid siRNA nanomedicine for hepatic and renal fibrosis","volume":"6","author":"Khaja","year":"2016","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0565","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00467-021-05352-w","article-title":"The potential of RNA-based therapy for kidney diseases","volume":"38","author":"Bondue","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcell.2015.00065","article-title":"Exosomes as renal inductive signals in health and disease, and their application as diagnostic markers and therapeutic agents","volume":"3","author":"Krause","year":"2015","journal-title":"Front Cell Dev Bio"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0575","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3390\/pharmaceutics13111810","article-title":"Efficient messenger RNA delivery to the kidney using renal pelvis injection in mice","volume":"13","author":"Oyama","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0580","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0585","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jconrel.2022.03.046","article-title":"The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs","volume":"345","author":"LoPresti","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0590","doi-asserted-by":"crossref","first-page":"21321","DOI":"10.1021\/jacs.1c09822","article-title":"Zwitterionic phospholipidation of cationic polymers facilitates systemic mRNA delivery to spleen and lymph nodes","volume":"143","author":"Liu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0595","doi-asserted-by":"crossref","first-page":"19937","DOI":"10.1021\/acsami.3c00494","article-title":"Spleen-targeted mRNA delivery by amphiphilic carbon dots for tumor immunotherapy","volume":"15","author":"Chen","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0600","doi-asserted-by":"crossref","first-page":"2404684","DOI":"10.1002\/advs.202404684","article-title":"Discovery of ketal-ester ionizable lipid nanoparticle with reduced hepatotoxicity, enhanced spleen tropism for mRNA vaccine delivery","volume":"11","author":"Lv","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0605","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/0023210-200923010-00003","article-title":"Getting into the brain: approaches to enhance brain drug delivery","volume":"23","author":"Patel","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0610","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4155\/tde.14.114","article-title":"Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas","volume":"6","author":"Chaichana","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0615","doi-asserted-by":"crossref","first-page":"2102610","DOI":"10.1002\/adhm.202102610","article-title":"Intranasal delivery of functionalized polymeric nanomaterials to the brain","volume":"11","author":"Zha","year":"2022","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0620","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0625","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/pharmaceutics15030746","article-title":"Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery","volume":"15","author":"Maher","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0630","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1853","article-title":"Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications","volume":"15","author":"Yang","year":"2023","journal-title":"WIREs Nanomed Nanobi"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0635","doi-asserted-by":"crossref","unstructured":"Noah N.M. Ndangili P.M. Polymeric nanosystems for neurological therapeutics in: Polymeric nanosystems, 2023, pp. 723\u2013759.","DOI":"10.1016\/B978-0-323-85656-0.00010-3"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0640","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jconrel.2022.08.049","article-title":"Delivery of self-replicating messenger RNA into the brain for the treatment of ischemic stroke","volume":"350","author":"Kim","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07994","article-title":"Lipid nanostructures for targeting brain cancer","volume":"7","author":"Nsairat","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0650","first-page":"100","article-title":"Solid lipid-based nanocarriers as efficient targeted drug and gene delivery systems, TrAC-trend","volume":"77","author":"Dolatabadi J.","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0655","doi-asserted-by":"crossref","DOI":"10.1038\/s41563-024-02114-5","article-title":"Blood\u2013brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system","author":"Wang","year":"2025","journal-title":"Nat. Mater."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0660","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neuropharm.2016.02.014","article-title":"Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound","volume":"120","author":"Poon","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0665","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2022.05.042","article-title":"Focused ultrasound\/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain","volume":"348","author":"Ogawa","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0670","doi-asserted-by":"crossref","first-page":"2208018","DOI":"10.1002\/adma.202208018","article-title":"Overcoming the blood\u2013brain barrier for gene therapy via systemic administration of GSH-responsive silica nanocapsules","volume":"35","author":"Wang","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0675","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3390\/life12081254","article-title":"The delivery of mRNA vaccines for therapeutics","volume":"12","author":"Nitika","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0680","first-page":"71","article-title":"Formulation and delivery technologies for mRNA vaccines","volume":"440","author":"Zeng","year":"2020","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0685","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1042\/EBC20160017","article-title":"The immune system","volume":"60","author":"Nicholson","year":"2016","journal-title":"Essays Biochem."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114325","article-title":"In vivo fate and intracellular trafficking of vaccine delivery systems","volume":"186","author":"Lee","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0695","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-021-00634-z","article-title":"A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct Tar"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0700","article-title":"Adverse effects following anti\u2013COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes","volume":"20","author":"Xie","year":"2022","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0705","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s13346-020-00725-4","article-title":"Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates","volume":"10","author":"Tan","year":"2020","journal-title":"Drug Deliv Transl Re"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0710","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3390\/pharmaceutics15031009","article-title":"DLin-MC3-containing mRNA lipid nanoparticles induce an antibody Th2-biased immune response polarization in a delivery route-dependent manner in mice","volume":"15","author":"Yavuz","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0715","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/vaccines11051003","article-title":"Comparison of the immune effects of an mRNA vaccine and a subunit vaccine against herpes zoster administered by different injection methods","volume":"11","author":"Lin","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0720","doi-asserted-by":"crossref","unstructured":"Mancino C., Pollet J., Zinger a. et al., Harnessing RNA technology to advance therapeutic vaccine antigens against Chagas disease, ACS Appl. Mater. Interfaces 16 (2024) 15832\u201315846. doi:https:\/\/doi.org\/10.1021\/acsami.3c18830.","DOI":"10.1021\/acsami.3c18830"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0725","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jconrel.2021.05.024","article-title":"The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2","volume":"335","author":"Huang","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0730","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s44222-022-00012-6","article-title":"Biomaterials for intranasal and inhaled vaccine delivery","volume":"1","author":"Cahn","year":"2023","journal-title":"Nat Rev Bioeng"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0735","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.actbio.2017.10.019","article-title":"Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses","volume":"64","author":"Li","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0740","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines8010123","article-title":"mRNA vaccines encoding the HA protein of influenza a H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice","volume":"8","author":"Zhuang","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0745","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1080\/17425247.2022.2131767","article-title":"Are inhaled mRNA vaccines safe and effective?","volume":"19","author":"Jansen","year":"2022","journal-title":"A review of preclinical studies, Expert Opin Drug Del"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0750","doi-asserted-by":"crossref","first-page":"1901935","DOI":"10.1002\/adma.201901935","article-title":"Oral delivery of biologics for precision medicine","volume":"32","author":"Dur\u00e1n-Lobato","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0755","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1146\/annurev-pharmtox-030320-092348","article-title":"Oral biologic delivery: advances toward oral subunit, DNA, and mRNA vaccines and the potential for mass vaccination during pandemics","volume":"61","author":"Coffey","year":"2021","journal-title":"Annu. Rev. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0760","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jconrel.2022.09.024","article-title":"Mucoadhesive carriers for oral drug delivery","volume":"351","author":"Kumar","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0765","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/vaccines11030673","article-title":"Intraduodenal delivery of exosome-loaded SARS-CoV-2 RBD mRNA induces a neutralizing antibody response in mice","volume":"11","author":"Zhang","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0770","doi-asserted-by":"crossref","first-page":"2219870","DOI":"10.1080\/10717544.2023.2219870","article-title":"PEGylated pH-responsive peptide-mRNA nano self-assemblies enhance the pulmonary delivery efficiency and safety of aerosolized mRNA","volume":"30","author":"Xu","year":"2023","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0775","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1016\/j.apsb.2022.03.011","article-title":"mRNA cancer vaccines: advances, trends and challenges","volume":"12","author":"He","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0780","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0785","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri1337","article-title":"TLR ligands from the natural world","volume":"4","author":"Honey","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0790","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1074\/jbc.M310175200","article-title":"mRNA is an endogenous ligand for toll-like receptor 3","volume":"279","author":"Karik\u00f3","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0795","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1158\/0008-5472.CAN-10-0699","article-title":"Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity","volume":"70","author":"Kreiter","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113900","article-title":"Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: getting the message across","volume":"176","author":"Minnaert","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0805","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0810","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/21645515.2016.1225635","article-title":"From discovery to licensure, the adjuvant system story","volume":"13","author":"Di","year":"2017","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0815","doi-asserted-by":"crossref","first-page":"2189885","DOI":"10.1080\/21645515.2023.2189885","article-title":"The matrix-M\u2122 adjuvant: a critical component of vaccines for the 21st century","volume":"19","author":"Stertman","year":"2023","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0820","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.addr.2008.12.008","article-title":"Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists","volume":"61","author":"Vollmer","year":"2009","journal-title":"Adv Drug DelivER Rev"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0825","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0830","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-4615-1823-5_10","article-title":"MF59 design and evaluation of a safe and potent adjuvant for human vaccines","volume":"6","author":"Ott","year":"1995","journal-title":"Pharm. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0835","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0840","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0845","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1249560","article-title":"Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive\u00ae CV9201 immunotherapy","volume":"5","author":"Hong","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0850","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12967-020-02218-x","article-title":"Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy","volume":"18","author":"Mauriello","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0855","doi-asserted-by":"crossref","unstructured":"Tockary T.A., Abbasi S., Matsui-Masai M. et al., Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment, bioRxiv(2022) 1\u201330. doi:https:\/\/doi.org\/10.1101\/2022.01.18.476829.","DOI":"10.1101\/2022.01.18.476829"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0860","doi-asserted-by":"crossref","first-page":"eabq3500","DOI":"10.1126\/sciadv.abq3500","article-title":"Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants","volume":"8","author":"Fan","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0865","doi-asserted-by":"crossref","first-page":"1153042","DOI":"10.3389\/fimmu.2023.1153042","article-title":"Potentials of saponins-based adjuvants for nasal vaccines","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0870","doi-asserted-by":"crossref","first-page":"1152855","DOI":"10.3389\/fimmu.2023.1152855","article-title":"Research progress in the development of natural-product-based mucosal vaccine adjuvants","volume":"14","author":"Gao","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0875","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102333","article-title":"Quality by design for mRNA platform purification based on continuous oligo-dT chromatography","volume":"35","author":"Qu","year":"2024","journal-title":"Mol Ther Nucl Acids"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0885","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3390\/vaccines11030661","article-title":"Emerging trends in lipid-based vaccine delivery: a special focus on developmental strategies, fabrication methods, and applications","volume":"11","author":"Karunakaran","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.159318","article-title":"Controlled preparation of lipid nanoparticles in microreactors: mixing time, morphology and mRNA delivery","volume":"505","author":"Chen","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0895","doi-asserted-by":"crossref","first-page":"257","DOI":"10.52711\/2231-5713.2022.00042","article-title":"The mRNA vaccine heralds a new era in vaccinology","volume":"12","author":"Shinde","year":"2022","journal-title":"Asian J Pharm Tech"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0900","unstructured":"Technical guidelines for pharmaceutical research of novel coronavirus prevention mRNA vaccines (to try out). (2020)."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0905","unstructured":"Organization W.H. Evaluation of the quality, safety and efficacy of messenger RNA vaccines for the prevention of infectious diseases: regulatory considerations. 1\u201366 (2021)."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0910","unstructured":"USP. Analytical procedures for mRNA vaccine quality (draft guidelines)- 2nd edition, https:\/\/www.uspnf.com\/notices\/analytical-procedures-mrna-vaccines-20230428, 2023, (accessed 15 October 2023)."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0915","article-title":"Lipid nanocarrier-based mRNA therapy: challenges and promise for clinical transformation","volume":"20","author":"Li","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0920","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0925","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00582-22","article-title":"Loss of Pfizer (BNT162b2) vaccine-induced antibody responses against the SARS-CoV-2 omicron vatiant tn adolescents and adults","volume":"96","author":"Gupta","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0930","doi-asserted-by":"crossref","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0935","doi-asserted-by":"crossref","first-page":"1051576","DOI":"10.3389\/fimmu.2022.1051576","article-title":"A novel mRNA vaccine, SYS6006, against SARS-CoV-2","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0940","doi-asserted-by":"crossref","DOI":"10.1093\/lifemeta\/load019","article-title":"Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled phase 1 trial","volume":"2","author":"Gui","year":"2023","journal-title":"Life Metabol"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0945","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12929-022-00853-8","article-title":"COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection","volume":"29","author":"Chi","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0950","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0955","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.jacc.2022.08.799","article-title":"Comparative risk of myocarditis\/pericarditis following second doses of BNT162b2 and mRNA-1273 coronavirus vaccines","volume":"80","author":"Naveed","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0960","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3201\/eid2807.212330","article-title":"Self-reported and physiologic reactions to third BNT162b2 mRNA COVID-19 (booster) vaccine dose","volume":"28","author":"Mofaz","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0965","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1056\/NEJMra2035343","article-title":"Maintaining safety with SARS-CoV-2 vaccines","volume":"384","author":"Castells","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0970","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3390\/biomedicines11082287","article-title":"'Spikeopathy': COVID-19 spike protein is pathogenic, from both virus and vaccine mRNA","volume":"11","author":"Parry","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0975","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/infdis\/jix342","article-title":"Toward understanding the outcomes of monkeypox infection in human pregnancy","volume":"216","author":"Kisalu","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0980","unstructured":"World Health Organization. Annexes to the vaccines and immunization for monkeypox interim guidance. (2022)."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0985","article-title":"Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: a rapid review on comparative benefits and risks","volume":"5","author":"Islam","year":"2022","journal-title":"Heal Sci Rep"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0990","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/v15051120","article-title":"Development of a multi-epitope universal mRNA vaccine candidate for monkeypox, smallpox, and vaccinia viruses: design and in silico analyses","volume":"15","author":"Rcheulishvili","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.106893","article-title":"Proteomics-based vaccine targets annotation and design of subunit and mRNA-based vaccines for Monkeypox virus (MPXV) against the recent outbreak","volume":"159","author":"Jin","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1000","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41422-023-00792-5","article-title":"Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens","volume":"33","author":"Fang","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41392-023-01432-5","article-title":"Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus","volume":"8","author":"Sang","year":"2023","journal-title":"Signal Transduct Tar"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.vaccine.2020.11.042","article-title":"Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials","volume":"39","author":"Dulin","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-Centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1473-3099(20)30016-5","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1030","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(19)30614-0","article-title":"Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial","volume":"20","author":"Clarke","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ebiom.2019.09.055","article-title":"Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge","volume":"49","author":"Marzi","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1040","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1016\/j.vaccine.2014.08.028","article-title":"Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents","volume":"32","author":"Wong","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1045","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(18)30165-8","article-title":"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study","volume":"18","author":"Huttner","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1050","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/infdis\/jix592","article-title":"Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease","volume":"217","author":"Meyer","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2023\/5560605","article-title":"Computational modeling and evaluation of potential mRNA and peptide-based vaccine against Marburg virus (MARV) to provide immune protection against hemorrhagic fever","volume":"2023","author":"Albaqami","year":"2023","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1060","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1070","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","article-title":"Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1075","article-title":"Co-existence and co-infection of influenza a viruses and coronaviruses: public health challenges","volume":"3","author":"Yang","year":"2022","journal-title":"Innovation (Camb)"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-022-00478-w","article-title":"Rational development of a combined mRNA vaccine against COVID-19 and influenza","volume":"7","author":"Ye","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1085","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.vaccine.2022.12.069","article-title":"Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022","volume":"41","author":"Moro","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1090","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1095","article-title":"A thermostable messenger RNA based vaccine against rabies","volume":"11","author":"Rupprecht","year":"2017","journal-title":"PLOS Neglect Trop D"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1100","doi-asserted-by":"crossref","first-page":"1099991","DOI":"10.3389\/fimmu.2022.1099991","article-title":"A single vaccination of nucleoside-modified rabies mRNA vaccine induces prolonged highly protective immune responses in mice","volume":"13","author":"Bai","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1105","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1110","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1115","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.immuni.2014.11.014","article-title":"Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved","volume":"41","author":"Wiehe","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ebiom.2014.10.022","article-title":"Vaccine-induced human antibodies specific for the third variable region of HIV-1 gp120 impose immune pressure on infecting viruses","volume":"1","author":"Zolla-Pazner","year":"2014","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1125","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1130","doi-asserted-by":"crossref","DOI":"10.1126\/science.aac4223","article-title":"HIV-1 neutralizing antibodies induced by native-like envelope trimers","volume":"349","author":"Sanders","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1126\/science.1225416","article-title":"Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses","volume":"337","author":"Burton","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1140","doi-asserted-by":"crossref","unstructured":"Tolbert W.D., Nguyen D.N., Tehrani Z.R. et al., Near-pan-neutralizing, plasma deconvoluted antibody N49P6 mimics host receptor CD4 in its quaternary interactions with the HIV-1 envelope trimer, mBio 12 (2021) e01274\u201301221. doi:https:\/\/doi.org\/10.1128\/mBio.01274-21.","DOI":"10.1128\/mbio.01274-21"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1145","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.4049\/jimmunol.165.8.4710","article-title":"HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response","volume":"165","author":"Weissman","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1150","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1155","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/vaccines9090959","article-title":"Enhancement of the HIV-1-specific immune response induced by an mRNA vaccine through boosting with a poxvirus MVA vector expressing the same antigen","volume":"9","author":"G\u00f3mez","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1160","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1097\/QAD.0000000000002026","article-title":"Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection","volume":"32","author":"Leal","year":"2018","journal-title":"Aids"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1165","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40537-022-00643-x","article-title":"Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development","volume":"9","author":"Wu","year":"2022","journal-title":"J. Big Data"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1170","article-title":"Identification of tumor antigens and immune subtypes of glioblastoma for mRNA vaccine development","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1175","doi-asserted-by":"crossref","unstructured":"Wang Z.-l., Huang R.-y., Han B. et al., Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development, Chin Neurosur J 8 (2022). doi:https:\/\/doi.org\/10.1186\/s41016-022-00301-4.","DOI":"10.1186\/s41016-022-00301-4"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1180","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1208\/s12249-025-03065-z","article-title":"Biomimetic nanoparticle based targeted mRNA vaccine delivery as a novel therapy for glioblastoma multiforme","volume":"26","author":"Ahmed","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines8030060","article-title":"Viral vector-based melanoma gene therapy","volume":"8","author":"Hromic-Jahjefendic","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1190","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ymthe.2017.11.009","article-title":"mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma","volume":"26","author":"Wang","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1195","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/sj.cgt.7700961","article-title":"Phase I\/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA","volume":"13","author":"Kyte","year":"2006","journal-title":"Can Gene Ther"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1200","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/sj.cgt.7700837","article-title":"Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination","volume":"12","author":"Kyte","year":"2005","journal-title":"Can Gene Ther"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1205","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00262-006-0222-y","article-title":"T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells","volume":"56","author":"Kyte","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1210","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1158\/1078-0432.CCR-08-2982","article-title":"Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients","volume":"15","author":"Bonehill","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1215","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00262-014-1642-8","article-title":"Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases","volume":"64","author":"Wilgenhof","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1220","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2015.63.4121","article-title":"Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma","volume":"34","author":"Wilgenhof","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1225","doi-asserted-by":"crossref","unstructured":"Tendeloo V.F.V., Velde A.V.d., Driessche A.V. et al., Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination, P Natl Acad Sci USA 107 (2010) 13824\u201313829. doi:https:\/\/doi.org\/10.1073\/pnas.1008051107.","DOI":"10.1073\/pnas.1008051107"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1230","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia","volume":"381","author":"Xu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1235","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2019.129437","article-title":"Progress in the understanding and treatment of Fabry disease","volume":"1864","author":"Miller","year":"2020","journal-title":"BBA-Gen. Subjects"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1240","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1245","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.ymthe.2018.05.014","article-title":"Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis","volume":"26","author":"Robinson","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.131802","article-title":"Genome editing and its role in vaccine, diagnosis, and therapeutic advancement","volume":"269","author":"Bisht","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1255","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2023.03.004","article-title":"Functional restoration of a CFTR splicing mutation through RNA delivery of CRISPR adenine base editor","volume":"31","author":"Amistadi","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1265","doi-asserted-by":"crossref","first-page":"11083","DOI":"10.1093\/nar\/gkaa816","article-title":"METTL3 counteracts premature aging via m6A-dependent stabilization of MIS12 mRNA","volume":"48","author":"Wu","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1270","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","article-title":"mRNA-based therapeutics: looking beyond COVID-19 vaccines","volume":"403","author":"Hamideh","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1275","first-page":"703","article-title":"Artificial intelligence-based framework for designing a novel mRNA vaccine","author":"Kong","year":"2023","journal-title":"Korean Society of Information Science"},{"key":"10.1016\/j.ijbiomac.2025.143134_bb1280","doi-asserted-by":"crossref","unstructured":"Hasanzadeh A., Hamblin M.R., Kiani J. et al., Could artificial intelligence revolutionize the development of nanovectors for gene therapy and mRNA vaccines? Nano Today (47) 2022 101665. doi:https:\/\/doi.org\/10.1016\/j.nanotod.2022.101665.","DOI":"10.1016\/j.nantod.2022.101665"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025036864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025036864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:27:18Z","timestamp":1782926838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025036864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":256,"alternative-id":["S0141813025036864"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143134","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA-based vaccines and therapies - a revolutionary approach for conquering fast-spreading infections and other clinical applications: a review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.143134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"143134"}}